BAMBOOS HEALTH CARE HOLDINGS LIMITED 百本醫護控股有限公司 (Incorporated in the Cayman Islands with limited liability) (Stock Code: 2293) NOTIFICATION LETTER 通知信函 Dear Non-registered Shareholder (Note 1) , 26 March 2025 The following document(s) of Bamboos Health Care Holdings Limited ("Company") has/have been prepared in English and Chinese and is/are available on the websites of the Company at www.bamboos.com.hk and The Stock Exchange of Hong Kong Limited at www.hkexnews.hk (collectively "Websites"):- • Interim Repo ...

BAMBOOS HEALTH CARE HOLDINGS LIMITED 百本醫護控股有限公司 (Incorporated in the Cayman Islands with limited liability) (Stock Code: 2293) NOTIFICATION LETTER 通知信函 Dear Registered Shareholder(s), 26 March 2025 The following document(s) of Bamboos Health Care Holdings Limited ("Company") has/have been prepared in English and Chinese and is/are available on the websites of the Company at www.bamboos.com.hk and The Stock Exchange of Hong Kong Limited at www.hkexnews.hk (collectively "Websites"):- • Interim Report 2024/202 ...

Financial Performance - For the six months ended December 31, 2024, the revenue was approximately HKD 39,500,000, a decrease of about 20.5% compared to approximately HKD 49,700,000 for the same period in 2023[5] - The profit before tax for the same period was approximately HKD 12,900,000, down approximately 38.6% from approximately HKD 21,000,000 in the previous year[5] - The profit attributable to equity holders of the company was approximately HKD 10,100,000, representing a decrease of about 40.9% from approximately HKD 17,100,000 in the prior year[5] - The operating profit for the period was HKD 13,821,000, a decrease from HKD 21,091,000 in the same period last year[7] - The basic and diluted earnings per share for the period were HKD 2.51, down from HKD 4.28 in the previous year[9] - The total comprehensive income for the period was HKD 15,836,000, which includes a profit of HKD 17,123,000[14] - The pre-tax profit for the six months ended December 31, 2024, was HKD 10,108,000, a decline of 41% from HKD 17,123,000 in the same period of 2023[38] - Basic earnings per share for the six months ended December 31, 2024, were HKD 2.51, down from HKD 4.28 in 2023, representing a decrease of 41%[38] - Profit for the period was approximately HKD 10,100,000, a decrease of about HKD 7,000,000 or 40.9% compared to approximately HKD 17,100,000 in the previous period[66] Dividends - The interim dividend declared on February 26, 2025, for the six months ended December 31, 2024, was HKD 10,061,500, equating to HKD 0.025 per ordinary share[5] - The interim dividend declared for the six months ended December 31, 2024, was HKD 10,062,000, compared to HKD 15,000,000 for the same period in 2023, a reduction of 33%[41] - The interim dividend for the previous period was HKD 0.050 per share, indicating a 50% decrease in dividend payout[116] Assets and Equity - Total assets as of December 31, 2024, were HKD 313,699,000, a slight decrease from HKD 318,062,000 as of June 30, 2024[11] - The company's total equity increased to HKD 222,734,000 from HKD 218,326,000 as of June 30, 2024[11] - The equity attributable to the company's equity holders increased to HKD 222,734,000 as of December 31, 2024, from HKD 218,326,000 as of July 1, 2024[14] - The company’s retained earnings as of December 31, 2024, were HKD 172,469,000, compared to HKD 176,608,000 as of July 1, 2023[14] Cash Flow - The net cash generated from operating activities for the six months ended December 31, 2024, was HKD 17,610,000, compared to a net cash used of HKD 501,000 in the same period of 2023[15] - The net cash used in investing activities was HKD 5,512,000 for the six months ended December 31, 2024, an increase from HKD 1,835,000 in the previous year[15] - The net cash used in financing activities decreased to HKD 13,331,000 from HKD 16,212,000 year-on-year[15] - The company's cash and cash equivalents at the end of the period were HKD 79,868,000, up from HKD 74,723,000 at the end of the previous year[15] Revenue Breakdown - Revenue from healthcare staffing solutions for the six months ended December 31, 2024, was HKD 32,573,000, a decrease of 20% compared to HKD 40,674,000 for the same period in 2023[28] - Total revenue for the group for the six months ended December 31, 2024, was HKD 39,471,000, down 20% from HKD 49,703,000 in the previous year[28] - Revenue from healthcare staffing solutions was approximately HKD 32,600,000, a decrease of about 20.0% from HKD 40,700,000 in the previous year, primarily due to the closure of COVID-19 testing centers and reduced demand for healthcare services[55] Expenses - Total expenses for the group decreased to HKD 120,584,000 in 2024 from HKD 155,490,000 in 2023, reflecting a reduction of approximately 22%[30] - The group incurred employee benefits expenses of HKD 14,329,000 for the six months ended December 31, 2024, an increase from HKD 12,212,000 in the previous year[33] - Employee benefits expenses increased to approximately HKD 14,300,000 from HKD 12,200,000, reflecting a rise in operational costs[63] Trade Receivables and Payables - Trade receivables as of December 31, 2024, were HKD 31,809,000, down from HKD 38,907,000 as of June 30, 2024[43] - Trade receivables decreased from approximately HKD 38,900,000 to HKD 31,800,000, a reduction of about HKD 7,100,000[67] - Trade payables increased from approximately HKD 20,800,000 to HKD 21,800,000, primarily due to an increase in payables aged over 90 days[68] Employee Information - As of December 31, 2024, the company employed a total of 75 employees, up from 55 employees as of June 30, 2024[83] - Total employee costs for the period amounted to approximately HKD 14,300,000, compared to HKD 12,200,000 for the six months ended December 31, 2023[83] Corporate Governance - The company has maintained compliance with the corporate governance code throughout the reporting period[110] - The roles of the chairman and CEO are separated, in accordance with the corporate governance code[111] - The audit committee, consisting of three independent non-executive directors, reviewed the interim results and confirmed compliance with applicable accounting policies and standards[114] - The board of directors is evaluating the effectiveness of the corporate governance structure, including the potential separation of the roles of chairman and CEO[113] Strategic Initiatives - The company plans to continue expanding its healthcare staffing solutions and related services in Hong Kong[17] - The company actively seeks strategic partnerships and expansion opportunities to increase service offerings and geographic coverage[58] Shareholder Information - The company’s major shareholder, Ms. Xi Xiaozhu, holds a 67.30% equity interest in the company, representing 270,864,000 shares[90] - Gold Empress holds 270,864,000 shares, representing 67.30% of the company's equity[94] - HRnet Group Limited owns 32,000,000 shares, accounting for 8.0% of the company's equity[94] Stock Options and Incentives - The company has a stock option plan that allows for the granting of options to eligible participants, with options for 1,850,000 shares at HKD 1.44 and 2,000,000 shares at HKD 0.994[91] - The total number of shares issued by the company as of December 31, 2024, is 402,460,000[90] - The company has adopted a share incentive plan effective from June 1, 2022, which is valid for ten years[83] - The total number of unexercised share options as of July 1, 2024, is 4,700,000[100] - The total number of stock options and reward shares available for grant as of July 1, 2024, and December 31, 2024, is 37,540,000 shares each[104]

Financial Performance - For the six months ended December 31, 2024, revenue was approximately HKD 39,500,000, a decrease of about 20.5% compared to HKD 49,700,000 for the same period in 2023[3] - Profit before tax for the same period was approximately HKD 12,900,000, down approximately 38.6% from HKD 21,000,000 in the previous year[3] - The profit attributable to equity holders of the company was approximately HKD 10,100,000, representing a decrease of about 40.9% from HKD 17,100,000 for the same period in 2023[3] - Operating profit for the period was HKD 13,821,000, down from HKD 21,091,000 in the previous year[4] - Total comprehensive income for the period was HKD 14,026,000, compared to HKD 15,836,000 for the same period in 2023[6] - Basic earnings per share for the six months ended December 31, 2024, were HKD 2.51, compared to HKD 4.28 for the same period in 2023, reflecting a decrease of approximately 41%[32] - The group reported a profit attributable to equity holders of HKD 10,108,000 for the six months ended December 31, 2024, down from HKD 17,123,000 in the previous year, a decline of about 41%[32] - The profit for the period is approximately HKD 10,100,000, a decrease of about 40.9% from approximately HKD 17,100,000 for the period ending December 31, 2023[58] Dividends - The company declared an interim dividend of HKD 10,061,500 (HKD 0.025 per share) for the six months ended December 31, 2024[3] - The interim dividend for the six months ending December 31, 2024, is set at HKD 2.5 per share, compared to HKD 5.0 per share for the same period last year[35] - The company declared a final dividend of HKD 15,000,000 (HKD 3.75 per share) for the year ending June 30, 2023[35] - The company plans to distribute an interim dividend of HKD 0.025 per share, totaling HKD 10,061,500, to shareholders on March 21, 2025[87] - The company will suspend the transfer of shares from March 12 to March 14, 2025, to facilitate the interim dividend distribution[88] Assets and Liabilities - Total assets as of December 31, 2024, were HKD 313,699,000, a slight decrease from HKD 318,062,000 as of June 30, 2024[8] - The total equity attributable to equity holders of the company was HKD 222,734,000, up from HKD 218,326,000 as of June 30, 2024[8] - Total liabilities decreased from HKD 99,736 thousand to HKD 90,965 thousand, a reduction of approximately 8.7%[10] - Current liabilities decreased from HKD 99,702 thousand to HKD 90,696 thousand, reflecting a decline of about 9.9%[10] - The company's total assets decreased slightly from HKD 318,062 thousand to HKD 313,699 thousand, a decline of approximately 1.1%[10] - Trade receivables as of December 31, 2024, amounted to HKD 31,809,000, down from HKD 38,907,000 as of June 30, 2024[37] - The net current assets decreased from approximately HKD 28,300,000 as of June 30, 2024 to approximately HKD 26,600,000 as of December 31, 2024[63] - Total outstanding borrowings amounted to HKD 62,000,000, classified as short-term loans[65] Cash Flow - Cash generated from operating activities was HKD 17,610 thousand, compared to a cash usage of HKD 501 thousand in the previous period[13] - Net cash used in investing activities was HKD 5,512 thousand, an increase from HKD 1,835 thousand in the prior period[13] - Net cash used in financing activities was HKD 13,331 thousand, down from HKD 16,212 thousand year-over-year[13] - Cash and cash equivalents at the end of the period totaled HKD 79,868 thousand, compared to HKD 74,723 thousand at the end of the previous period[13] - As of December 31, 2024, the group maintained cash and cash equivalents of approximately HKD 79,900,000, a decrease from HKD 81,100,000 as of June 30, 2024[63] - Cash and bank balances were reported at HKD 79,615,000 as of December 31, 2024, compared to HKD 80,936,000 as of June 30, 2024[39] Employee Expenses - Employee benefit expenses increased to HKD 14,329,000 from HKD 12,212,000 in the previous year[4] - The group’s employee benefit expenses, including director remuneration, increased to HKD 14,329,000 in the six months ended December 31, 2024, from HKD 12,212,000 in the same period of 2023, an increase of about 17%[28] - Employee costs for the period totaled approximately HKD 14,300,000, compared to HKD 12,200,000 for the six months ended December 31, 2023[75] Strategic Focus - The group is focused on maintaining financial stability amid geopolitical tensions and inflation pressures while pursuing strategic partnerships and service expansion opportunities[49] - The company aims to reallocate its investment portfolio in response to current market conditions and future developments[46] - The group had no major future investment or capital asset plans as of December 31, 2024[73] Corporate Governance - The company is committed to maintaining high standards of corporate governance and transparency to protect the interests of shareholders[82] - The board will continue to review the effectiveness of the corporate governance structure, including the separation of the roles of Chairman and CEO[85] - The audit committee, consisting of three independent non-executive directors, has reviewed the interim results and confirmed compliance with applicable accounting policies and standards[86] - The company has adopted the standard code of conduct for securities trading as per the listing rules, ensuring compliance by directors during the period[81] Employment and Personnel - The group employed a total of 75 employees as of December 31, 2024, an increase from 55 employees as of June 30, 2024[75] - The group has approximately 30,000 registered healthcare personnel as of December 31, 2024[47] Other Income and Expenses - The group incurred income tax expenses of HKD 2,798,000 for the six months ended December 31, 2024, compared to HKD 3,893,000 in the same period of 2023, a decrease of approximately 28%[30] - The group’s interest income from bank deposits was HKD (808,000) for the six months ended December 31, 2024, slightly improved from HKD (856,000) in the previous year[28] - Other income for the period is approximately HKD 700,000, an increase from HKD 400,000 for the period ending December 31, 2023[54] Market Conditions - The group had no significant foreign currency risk as most transactions were conducted in HKD[64] - The group expects no significant impact from newly issued accounting standards on its current or future reporting periods[23]

EF001 第 1 頁 共 2 頁 v 1.1.1 EF001 發行人所發行上市權證/可轉換債券的相關信息 發行人所發行上市權證/可轉換債券 不適用 其他信息 其他信息 不適用 發行人董事 本公司的執行董事為奚曉珠小姐及鄭守崗先生，以及獨立非執行董事為陳繼宇博士丶王幹文先生及林國明先生。 免責聲明 第 2 頁 共 2 頁 v 1.1.1 | 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因 | | | --- | --- | | 公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 | | | 股票發行人現金股息公告 | | | 發行人名稱 | 百本醫護控股有限公司 | | 股份代號 | 02293 | | 多櫃檯股份代號及貨幣 | 不適用 | | 相關股份代號及名稱 | 不適用 | | 公告標題 截至二零二四年十二月三十一日止六個月之中期股息 | | | 公告日期 | 2025年2月26日 | | 公告狀態 | 新公告 | | 股息信息 | | | 股息類型 | 中期（半年期） | | 股息性質 | 普通股 ...

百 本 醫 護 控 股 有 限 公 司（「本公司」）董 事 會（「董事會」）謹 此 宣 佈，董 事 會 會 議 將 於 二 零 二 五 年 二 月 二 十 六 日（星 期 三）舉 行，旨 在（其 中 包 括）批 准 刊 發 本 公 司 及 其 附 屬 公 司 截 至 二 零 二 四 年 十 二 月 三 十 一 日 止 六 個 月 的 中 期 業 績 公 告，以 及 考 慮 宣 派 中 期 股 息（如 有）。 承董事會命 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示 概 不 就 因 本 公 告 全 部 或 任 何 部 分 內 容 而 產 生 或 因 倚 賴 該 等 內 容 而 引 致 之 任 何 損 失 承 擔 任 何 責 任。 BAMBOOS HEALTH CARE HOLDINGS LIMITED 百 本 醫 護 控 股 有 限 公 司 （ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ） （股份代號：2293） 董事會會議日期 奚曉珠 香 港，二 零 二 五 年 二 月 七 日 ...

（ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ） （股份代號：2293） 董事名單及其角色及職能 百 本 醫 護 控 股 有 限 公 司 董 事 會（「董事會」）成 員 載 於 下 文： 執 行 董 事： 奚曉珠女士 （主 席 兼 行 政 總 裁） 鄭守崗先生 獨 立 非 執 行 董 事： 陳繼宇博士 王幹文先生 林國明先生 BAMBOOS HEALTH CARE HOLDINGS LIMITED 百 本 醫 護 控 股 有 限 公 司 C－主 席 M－成 員 香 港，二 零 二 四 年 十 二 月 一 日 董 事 會 有 三 個 委 員 會。下 表 提 供 各 董 事 會 成 員 在 該 等 委 員 會 所 履 行 職 務 的 成 員 資 料： | | 董事會委員會 | | | | --- | --- | --- | --- | | 董 事 | 審核委員會 | 薪酬委員會 | 提名委員會 | | 奚曉珠女士 | – | – | C | | 鄭守崗先生 | – | – | – | | 陳繼宇博士 | M | M | M | | 王幹文先生 | C | M | – | | 林國明先生 | M | ...

百 本 醫 護 控 股 有 限 公 司 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示 概 不 就 因 本 公 告 全 部 或 任 何 部 分 內 容 而 產 生 或 因 倚 賴 該 等 內 容 而 引 致 之 任 何 損 失 承 擔 任 何 責 任。 BAMBOOS HEALTH CARE HOLDINGS LIMITED （ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ） （股份代號：2293） 於二零二四年十一月二十八日舉行的 股東週年大會的投票結果 摘 要 董 事 會 欣 然 宣 佈，於 股 東 週 年 大 會 上 提 呈 的 所 有 決 議 案 均 獲 股 東 以 投 票 方 式 正 式 通 過。 於 百 本 醫 護 控 股 有 限 公 司（「本公司」）於 二 零 二 四 年 十 一 月 二 十 八 日 舉 行 的 股 東 週 年 大 會（「股東週年大會」）上，股 東 週 年 大 會 主 席 要 求 以 投 票 方 式 就 日 期 為 二 零 二 四 年 十 月 二 十 五 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示 概 不 就 因 本 公 告 全 部 或 任 何 部 分 內 容 而 產 生 或 因 倚 賴 該 等 內 容 而 引 致 之 任 何 損 失 承 擔 任 何 責 任。 BAMBOOS HEALTH CARE HOLDINGS LIMITED 百 本 醫 護 控 股 有 限 公 司 （股份代號：2293） 於 本 公 告 日 期，除 上 文 所 披 露 者 外，鄭 先 生(i)於過去三年並無在其他香港及海 外 上 市 公 眾 公 司 擔 任 任 何 董 事 職 務；(ii)並無於本公司及本集團其他成員公司 擔 任 任 何 其 他 職 位 或 擁 有 任 何 其 他 主 要 的 委 任 及 專 業 資 格，彼 亦 無 與 任 何 董 事、本 公 司 高 級 管 理 層、主 要 股 東 或 控 股 股 東 有 任 何 其 他 關 係；及(iii)並無於本 公 司 股 份 中 擁 有 任 何 其 他 權 益（定 義 見 香 港 法 例 第571章證券及期貨條 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本通告之內容概不負責，對其準確性或 完整性亦不發表任何聲明，並明確表示概不就因本通告全部或任何部分內容而產生或因倚賴該等 內容而引致之任何損失承擔任何責任。 BAMBOOS HEALTH CARE HOLDINGS LIMITED 百本醫護控股有限公司 （於開曼群島註冊成立的有限公司） （股份代號：2293） 股東週年大會通告 茲通告百本醫護控股有限公司（「本公司」）謹訂於二零二四年十一月二十八日（星期四）上午 十一時正在香港九龍旺角彌敦道612–618號好望角大廈8樓801室舉行股東週年大會（「大會」），以 考慮並酌情處理下列事項： 普通決議案 作為特別事項 – 1 – 1. 省覽及批准本公司及其附屬公司截至二零二四年六月三十日止年度的經審核綜合財 務報表及本公司董事（「董事」）會報告及核數師報告。 2. 重選奚曉珠小姐為執行董事。 3. 重選陳繼宇博士為獨立非執行董事。 4. 授權董事會（「董事會」）釐定董事酬金。 5. 續聘國衛會計師事務所有限公司為本公司截至二零二五年六月三十日止年度之核數 師，並授權董事會釐定其酬金。 6. 批准派付截至二零二四年六月 ...